Benign Prostatic Hyperplasia — CPB 0079 | AETNA Coverage Update

Aetna modified CPB 0079 for benign prostatic hyperplasia treatment, effective January 14, 2026. Here's what billing teams need to act on now.

Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0079 governing BPH treatment coverage. The revision affects a wide range of procedures — from aquablation (CPT 0421T) and prostatic urethral lift (CPT 52441, 52442) to prostatic arterial embolization (CPT 37243) and temporary prostatic devices like the iTind (CPT 53865, 53866). Several technologies remain experimental under this updated coverage policy, and new additions to the exclusion list create real claim denial risk if your team hasn't reviewed the full criteria.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Benign Prostatic Hyperplasia — CPB 0079
Policy Code	CPB 0079
Change Type	Modified
Effective Date	January 14, 2026
Impact Level	High
Specialties Affected	Urology, Interventional Radiology, Interventional Urology
Key Action	Audit charge capture for CPT 0421T, 52441–52442, 53865–53866, and 0950T before billing any Aetna BPH claims after January 14, 2026

---

Aetna BPH Coverage Criteria and Medical Necessity Requirements 2026

The Aetna BPH coverage policy treats TURP as the reference standard. Every procedure on the covered list is considered medically necessary as an alternative to TURP — not a first-line option with no threshold. That framing matters for documentation.

Alpha-blockers and hormonal agents — alfuzosin, doxazosin, silodosin, tamsulosin, terazosin, finasteride, dutasteride, and dutasteride-plus-tamsulosin — meet medical necessity criteria under this policy. Tadalafil at 5 mg daily also qualifies, but check individual plan exclusions. Some Aetna plans carve out tadalafil entirely.

Procedural coverage is broad. Aquablation (CPT 0421T, HCPCS C2596), laser prostatectomy including HoLEP, HoLAP, and HoLRP (CPT 52647, 52648, 52649), prostatic arterial embolization (CPT 37243), prostatic urethral lift or UroLift (CPT 52441, 52442; HCPCS C9739, C9740), TUMT (CPT 53850), Rezum water vapor therapy/TUNA (CPT 53854), transurethral electrovaporization (TUVP), and TUIP (CPT 52450) all meet the medical necessity standard.

CPT 53855 — insertion of a temporary prostatic urethral stent — is also covered under CPB 0079. If your practice performs temporary stenting as part of BPH management, confirm your documentation supports the medical necessity criteria in the policy before billing.

The UroLume endourethral stent (CPT 52282) has specific age and anatomic criteria. The patient must be at least 60 years old — or under 60 and a poor surgical candidate — and the prostate must measure at least 2.5 cm in length. UroLume also covers recurrent bulbar urethral stenosis when dilation, urethrotomy, or urethroplasty have already failed.

Temporary prostatic devices — specifically the iTind (CPT 53865, 53866; HCPCS C9769) — require two criteria: prostate volume between 25 and 75 g, and no median lobe obstruction. Both must be documented before billing. Missing either criterion puts that claim at risk.

This coverage policy does not explicitly list prior authorization requirements within the CPB, but Aetna's broader utilization management program applies to most surgical procedures. Confirm prior auth requirements for CPT 0421T (aquablation), CPT 37243 (embolization), and CPT 52649 (laser enucleation) directly with Aetna before scheduling.

---

Aetna BPH Exclusions and Non-Covered Indications

This is where CPB 0079 creates real exposure. Aetna classifies the following as experimental, investigational, or unproven — and claims for these procedures will deny on Aetna BPH billing:

Four additional CPT codes — 0619T, 0655T, 0714T, and 0867T — appear in a separate section of the source policy related to a distinct technology assessment (the Prosta-Seq/seminal cell free DNA group). These codes are not listed under the core BPH experimental interventions section. Their coverage status for standard BPH indications requires direct review of the full CPB 0079 policy text. Do not assume these are covered for BPH without that review.

The drug-coated balloon exclusion is worth flagging specifically. CPT 52284 (cystourethroscopy with mechanical urethral dilation and therapeutic drug delivery by drug-coated balloon) is listed in the non-covered group. If your practice added Optilume to its procedure mix in 2025, those Aetna claims will not get paid under this policy.

HIFU is another one to watch. CPT 0950T — transrectal HIFU ablation of prostate tissue — is explicitly experimental under CPB 0079. This mirrors Aetna's consistent position on HIFU across multiple policies. Don't submit 0950T for BPH indications expecting coverage.

Also note: covered procedures like laser prostatectomy, ILCP, prostatic urethral lift, TUVP, TUIP, TUMT, TUNA, and ultrasonic aspiration lose their covered status when billed for indications other than BPH. Off-label use of these codes for non-BPH conditions is experimental under this policy. Your coding and documentation must tie directly to the BPH diagnosis.

---

Coverage Indications at a Glance

---

Aetna BPH Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for BPH Under CPB 0079

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Not Covered / Experimental CPT Codes

Note: CPT codes 37242, 37244, and 75894 appear in the source policy under an ambiguous code group alongside covered embolization codes. Their coverage status for BPH cannot be definitively established from the available policy data. Review the full CPB 0079 policy text directly before billing these codes for BPH indications.

HCPCS Codes Requiring Direct Policy Review

Key ICD-10-CM Diagnosis Codes

The full ICD-10-CM list under CPB 0079 includes 88 codes. Review the complete code set at the Aetna policy source for BPH-specific N40.x codes and associated lower urinary tract symptom diagnoses.

---